DUBLIN, May 10, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022" report to their offering.
The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment is expected to witness the fastest growth, a CAGR of 4.3% during the forecast period.
Osteoporosis disease is the most common bone disease occurring due to reduced bone mineral density, thus increasing risk of fractures and fragile bones. It leads to abnormally porous bones such as sponge, which facilitates weakening of bones and painful fracture. Bone mineral density decreases naturally with age, and hence aging population face high risks of osteoporosis. The decline in bone strength is only visible after the bone gets fractured. Most of the spine, hip, shoulder and forearm fractures occur in aged people of 65 years and above. One of the major procedures to build stronger muscle and bones is exercising regularly during the teenage years, which in turn leads to a lower risk of osteoporosis disease. The increasing trend of inactive lifestyle and obesity leads to growing prevalence of osteoporosis disease.
Some of the signs and symptoms of the osteoporosis are falling risk and fractures. Diagnostic tests of osteoporosis include X-Ray test and traditional radiography tests, which is further confirmed with the help of bone density test. Osteoporosis disease can be managed by nutrition emphasis, lifestyle management and medicines. According to National Osteoporosis Foundation, by 2025 osteoporosis would lead to approximately three million fractures.
Based on drug class, the global osteoporosis drugs market has been segmented as bisphosphonates, parathyroid hormone therapy, SERM's, rank ligand inhibitor, calcitonin, and others. The bisphosphonates segment dominated the global market in 2015.
The global osteoporosis drugs market is growing due to growing geriatric population, increasing prevalence of osteoporosis in postmenopausal women and increasing healthcare expenditure. The increasing focus on research & development of new drugs for treatment of osteoporosis and increasing awareness of osteoporosis are also driving the growth of the global osteoporosis drugs market.
The restraints for the growth of the global osteoporosis drugs market include strict regulatory requirements for the approval of drugs and patent expiry of blockbuster drugs. The side-effects and complications associated with administration of osteoporosis drugs such as nausea, ulcer in stomach and irritable bowel syndrome are also hindering the growth of the global market.
Geographically, North America is expected to continue being the largest market for osteoporosis drugs globally, during 2016-2022. It is due to growing geriatric population and increasing awareness of osteoporosis. The European osteoporosis drugs market is growing at a significant rate mainly due to growing aging population, increasing prevalence of osteoporosis in postmenopausal women and increasing awareness of osteoporosis. However, the Asia-Pacific market of osteoporosis drugs is expected to witness the highest growth during the forecast period. This is due the growing geriatric population, increasing healthcare expenditure, large pool of patients, modifying lifestyle and increasing awareness of osteoporosis in the region.
Some of the key companies operating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc., and Amgen Inc.
Key Topics Covered:
1. Research Scope And Methodology
2. Executive Summary
3. Market Outlook
3.1.2 Signs And Symptoms
3.1.4 Prevention And Treatment
3.2 Trends In The Global Osteoporosis Drug Market
3.2.1 Increasing Awareness Of Osteoporosis Care
3.3 Factors Driving Growth Of The Market And Its Impact On Market Forecast
3.3.1 Increasing Prevalence Of Osteoporosis
3.3.2 Rapid Urbanization Affecting Bone Health
3.3.3 Increasing Prevalence Of Osteoporosis In Post-Menopausal Women
3.3.4 Increasing Healthcare Expenditure
3.3.5 Growing Geriatric Population
3.3.6 Increasing R&D Investment In Drug Discovery And Development
3.3.7 Impact Analysis Of Drivers On Market Forecast
3.4 Factors Hindering Growth Of The Market And Its Impact On Market Forecast
3.4.1 Side-Effects And Complications Associated With Administration Of Osteoporosis Drug
3.4.2 Patent Expiration Of Osteoporosis Drug
3.4.3 Limited Healthcare Reimbursement
3.4.4 Impact Analysis Of Restraints On Market Forecast
4. Drug Approval Process In U.S. And Europe
4.1 Drug Approval Process In The U.S.
4.2 Drug Approval Process In The Eu
5. Global Osteoporosis Drug Market Size And Forecast (2012-2022)
5.1 Global Osteoporosis Drug Market, By Drug Type
5.2 Global Osteoporosis Drug Market, By Region
6. Global Osteoporosis Drug Market, By Drug Type
6.1 Bisphosphonates Market
6.1.1 Global Bisphosphonates Market, By Region
6.2 Parathyroid Hormone Therapy Market
6.2.1 Global Parathyroid Hormone Therapy Market, By Region
6.3 Calcitonin Market
6.3.1 Global Calcitonin Market, By Region
6.4 Selective Estrogen Receptor Modulator (Serm) Market
6.4.1 Global Serm Market, By Region
6.5 Rank Ligand Inhibitor Market
6.5.1 Global Rank Ligand Inhibitor Market, By Region
7. Global Osteoporosis Drug Market, By Geography
8. Competitive Analysis
9. Company Profiles And Strategic Developments
- Pfizer, Inc.
- Eli Lily And Company
- F. Hoffmann La Roche
- Novartis Ag
- Merck & Co., Inc.
- Amgen, Inc.
- Radius Health, Inc.
- Teva Pharmaceutical Industries Ltd.
- Glaxosmithkline Plc
For more information about this report visit http://www.researchandmarkets.com/research/j78qph/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-883-billion-osteoporosis-drugs-market-growth-and-demand-forecast-to-2022---key-companies-are-eli-lilly-and-co-pfizer-f-hoffmann-la-roche-novartis-merck--co-inc-and-amgen-300454274.html
SOURCE Research and Markets